Quest Diagnostics — Jan 12, 2026 release
Fiscal 2025 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0000947871-26-000025
Showing in the filing
High-growth areas channel growth
“>20% CAGR”
Period
The long term
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 25
Revenue CAGR for FY2025
“4% - 5%”
Total revenues CAGR for FY2025
“4% - 5% CAGR”
Physicians channel growth for the long term
“4% - 5% CAGR”
Hospitals channel growth for the long term
“5% - 6% CAGR”
High-growth areas channel growth for the long term
“>20% CAGR”
Adjusted EPS CAGR for the long term
“7% - 9%”
CoLab revenues for FY2026
“~$1B in revenues in 2026 including Corewell Health”
Advanced diagnostic tests in 5 key clinical …
“double-digit growth”
Advanced diagnostic tests in 5 key clinical … for FY2025
“~$1 billion”
Invigorate productivity and cost savings tar… for FY2025
“3% annual productivity and cost savings target”
M&A targeted financial criteria - EPS accret…
“Accretive to adj EPS in year 1”
M&A targeted financial criteria - ROIC accre…
“Accretive to ROIC (at least 10%) by year 3”
Targeted capital deployment - operating cash… for FY2025
“$4.5B - $5.0B operating cash flow”
Targeted capital deployment - capital expend… for FY2025
“$1.5B - $1.7B capital expenditures (~4.5% of revenue)”
Targeted capital deployment - free cash flow for FY2025
“$3.0B - $3.3B free cash flow”
Targeted capital deployment - acquisitions for FY2025
“~$1.5B acquisitions”
Targeted capital deployment - acquisitions r… for FY2025
“Drives 1% - 2% revenue growth”
Targeted capital deployment - dividends for FY2025
“~$1.0B dividends”
Targeted capital deployment - share repurcha… for FY2025
“~$0.7B share repurchases”
Total revenues
“4% - 5% CAGR”
Total revenues - acquisition contribution for FY2025
“Includes 1% - 2% growth from new acquisitions”
Operating margins for FY2027
“+75 to +150 basis points by the end of 2027”
Adjusted EPS* for the long term
“7% - 9% CAGR”
Free cash flow for FY2025
“Free cash flow growth commensurate with earnings growth”
Adjusted EPS growth plus dividend yield CAGR for FY2025
“high single-digit to low double-digit CAGR”
Exhibit 99.1 · the passage around this item
… earlier in the release
Any references to free cash flow refer to cash flow from operations less capital expenditures.
WHY WE EXIST
PURPOSE
The Quest Way
STRATEGY
HOW WE GROW
CULTURE
HOW WE WORK
PURPOSE WHY WE EXIST
Working together to create a healthier world, one life at a time
STRATEGY HOW WE GROW
We are connecting consumers and clinicians to innovative, affordable, and actionable insights that illuminate every person's path to better health, at every stage of life.
CULTURE HOW WE WORK
The 5Cs
Customer first
Care
Collaboration
Continuous improvement
Curiosity
Quest Diagnostics is at the center of healthcare
50% US hospitals and physicians served annually
1/3 US adults served annually
~217M requisitions in 2024
~8K patient access sites
~5K vehicles
>90% of insured lives in the US
>>80B patient data points
>55K employees
~850 MDs/PhDs
~1,600 patents/patents pending
Global including in Canada through LifeLabs
Our lab testing informs every stage of a person's health journey
Risk evaluation
What is my risk of getting a disease?
Periodic screening
How is my overall health?
Diagnosis
What is making me sick?
Prognosis
What direction wil my sickness take?
Therapy selection
What therapy is best for me?
Therapy monitoring
Is my therapy working?
Follow-up care
Is my success sustainable?
Prevention and wellness testing
Chronic disease and sick-care testing
Growing healthcare trends continue to favor Quest
Demographic shifts- older, sicker population
Innovations in lab diagnostics
Greater adoption of AI and automation
Consumer focus on prevention and wellness
We are well positioned in the nearly $90 billion US lab market
Physician Channel $58B
POL 11%
Quest 12%
Hospital Outreach 35%
Other independent Labs 42%
2% - 4% CAGR
2024 Total US Lab Market $89B
Physician 65%
Hospital 35%
1% - 3% CAGR
Hospital Channel $31B
Quest 6%
Other Ind Labs 14%
Other Hospital 80%
1% - 2% CAGR
2024 Total Canadian Lab Market ~$5B
LifeLabs 13%
Community Labs 8%
Hospital/Public Health 79%
~3%CAGR
LifeLabs
British Columbia
Saskatchewan
Ontario
41M people
Leading provider of clinical laboratory testing in Canada
Headquartered in Toronto
5 primary labs and 350 collection centers
Strong growth opportunities in Canada
Broadening access to lab services, including advanced diagnostics
Expanding into new provinces
Increasing consumer interest
Our strategy supports above-market growth in key channels
Physicians
4% - 5% CAGR
Capitalize on expanded health
plan network access
Extend geographic reach
Serve as a partner of choice for large enterprise customers
Hospitals
5% - 6% CAGR
Deliver scaled reference testing
Provide Collaborative Lab Solutions
Expand in new geographies through outreach acquisitions
High-growth areas
>20% CAGR
Grow consumer-initiated testing
Support life sciences partners with testing and services
Deliver data analytics insights
Lead in advanced diagnostics through science and innovationDeliver a better customer experience and productivity improvements through technology
Long-term outlook beyond 2025: 4% - 5% revenue CAGR and 7% - 9% adjusted EPS CAGR
Our unique strengths enable us to capitalize on physician market trends
Physician employment trends
CAGR
Independent
35%
22%
-11%
Corporate entity
17%
23%
+8%
Health System
48%
55%
+3%
2020
2024
Enterprise accounts
Summit Health City MD
Oak St. Health
Optum
Minute clinic
duly
Healthcare provider and executive needs
Scaled, efficient diagnostic testing to alleviate staff burden and gain external expertise
Reduced cost in testing capital and infrastructure--and minimized regulatory risks
Access to technology, automation, and broader menus of advanced testing
Optimized billing, reimbursement, and insurance in-network status for test coverage
Ability to focus on quality patient care with faster turnaround time and greater reliability
Our strengths enable us to meet each of these needs
Scale
Board access (PSCs, IOPs
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.